Detalhe da pesquisa
1.
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
Lancet Oncol
; 23(2): 248-258, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35030333
2.
A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer.
Eur J Cancer
; 202: 114007, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38518534
3.
Management of Fibroblast Growth Factor Inhibitor Treatment-emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
Eur Urol Open Sci
; 50: 1-9, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37101768
4.
Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial.
Eur Urol
; 79(3): 334-338, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33461782
5.
Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry.
Clin Genitourin Cancer
; 15(6): e1069-e1072, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28882737
6.
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.
J Clin Oncol
; 35(35): 3916-3923, 2017 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28902533
7.
Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T.
Target Oncol
; 10(3): 423-7, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25466382